AFAlessandra Ferrario

Alessandra Ferrario

*This is an algorithmically generated author record based on publicly available information.

Alessandra Ferrario has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Public perceptions of mortality studies in conflict-affected areas of the Eastern Mediterranean Region: an exploratory study

    by Esra Abdallah Abdalwahed Mahgoub, Ali Alshalah, Farah El Halabi, Manasik Mamoun, Azzam Ali Mohammad Fare’A, Leina Elomeiri, Sajjad Alazzawi, Abdirahman Khalif Mohamud, Awni Mokhtar Sallam Ali Awn, Mohammed Aref Ali Saeed Ahmed, et al.

    Background: Mortality surveys in conflict-affected settings are essential for documenting the human cost of armed conflict, guiding the humanitarian response, and promoting accountability. The success of such studies relies on the participation of the affected populations. Yet, we know little about how the public in conflict-affected countries perceives such studies, their willingness to participate, or the barriers they face to participate. This study aimed to explore public perceptions, willingness and barriers to participate in mortality surveys in six conflict-affected countries of the Eastern Mediterranean Region. Methods: An exploratory, cross-sectional mixed-methods study was conducted in Sudan, Somalia, Syria, Lebanon, Iraq, and Yemen between March and June 2025. An online self-administered questionnaire captured both quantitative and qualitative data. Quantitative data were analyzed using descriptive statistics and bivariate tests, while qualitative responses underwent inductive content analysis. Results: Among 3455 participants (median age 29 years; 56.5% female), 94% ( n = 3254) considered mortality surveys during armed conflicts important. Two-thirds (66.7%, n = 2306) expressed willingness to participate in mortality surveys, with a preference for electronic surveys. Willingness to participate was positively associated with older age, male sex, nationality, presence in the country during conflict, comfort with data sharing in social media, and absence of perceived cultural and religious barriers ( p < 0.05). More than 40% of respondents reported trusting to provide death data to the government (44.3%, n = 1529) and international organizations (43.8%, n = 1515). Respondents reporting no trust to provide this data mentioned lack of credibility and political bias were the main reasons for distrust. Only 13.1% ( n = 453) of the respondents perceived mortality surveys as harmful; key concerns included retaliation, political manipulation, and psychological distress. 19% ( n = 658) cited cultural or religious barriers, most linked to sectarianism, honor, and the sanctity of death, as an obstacle to participation. Conclusion: Perceptions captured across the six conflict-affected EMR countries among the digitally-active adult respondents reflect both recognition of the importance of mortality surveys and concerns about safety, trust, and cultural sensitivities. Enhancing confidentiality, engaging trusted institutions in data collection, and adopting culturally sensitive approaches are critical to strengthening participation and ensuring the ethical implementation of mortality surveys in conflict zones.


  • Open Access

    Measuring conflict related mortality in ten countries of the WHO Eastern Mediterranean Region (2004–2024): A scoping review

    by Esra Abdallah Abdalwahed Mahgoub, Alessandra Ferrario

    Armed conflict is an important contributor to the global burden of disease through direct and indirect morbidity and mortality. Yet, reliable, up-to-date, and broadly accepted estimates of the human toll are scarce. We conducted a scoping review to map methods used to estimate conflict-related deaths in ten countries of the WHO Eastern Mediterranean region using publicly available data sources. We searched three bibliomedical and scientific databases, manually searched conflict-related death databases and government websites, and reviewed websites of key humanitarian partners. In total, 69 peer-reviewed articles (from 2004 to 2024), 23 databases, 12 government sources, and 114 nutrition and mortality survey reports (from 2004 to 2024) were included. Iraq (32/69, 46%) was the most frequently studied country in the peer-reviewed literature, followed by Syria (16/69, 23%) and Yemen (14/69, 20%). About two-thirds of the studies in the peer-reviewed literature used secondary data (45/69, 65%), frequently from passive surveillance (28/69, 41%) and were national in scope (40/69, 58%). Total number of deaths was the most reported outcome in the peer-reviewed literature (63/69, 91%), followed by crude mortality rate (22/69, 32%). In 54 out of 69 studies (78%), the first author was affiliated with an institution outside the region. Among these 54 studies, only 19 had at least one co-author affiliated with an institution from the region. Databases were mostly based on passive surveillance compiling data from media reports (14/23, 61%), humanitarian organizations (9/23, 39%) and Government sources (8/23, 35%). Nutrition and mortality surveys were based on primary data collection, mostly sub-national and in some cases surveyed more frequently countries under-represented in the peer-reviewed literature. The extensive use of databases suggests a strong interest in comparable longitudinal data on mortality in conflict settings. There may be an untapped opportunity for greater use of survey data by a wider audience.


  • Use of Palliative Care Among Commercially Insured Patients With Metastatic Cancer Between 2001 and 2016

    by Alessandra Ferrario, Fang Zhang, Dennis Ross-Degnan, J. Frank Wharam, Martha L. Twaddle, Anita K. Wagner

    PURPOSE: Early palliative care, concomitant with disease-directed treatments, is recommended for all patients with advanced cancer. This study assesses population-level trends in palliative care use among a large cohort of commercially insured patients with metastatic cancer, applying an expanded definition of palliative care services based on claims data.METHODS: Using nationally representative commercial insurance claims data, we identified patients with metastatic breast, colorectal, lung, bronchus, trachea, ovarian, esophageal, pancreatic, and liver cancers and melanoma between 2001 and 2016. We assessed the annual proportions of these patients who received services specified as, or indicative of, palliative care. Using Cox proportional hazard models, we assessed whether the time from diagnosis of metastatic cancer to first encounter of palliative care differed by demographic characteristics, socioeconomic factors, or region.RESULTS: In 2016, 36% of patients with very poor prognosis cancers received a service specified as, or indicative of, palliative care versus 18% of those with poor prognosis cancers. Being diagnosed in more recent years (2009-2016 v 2001-2008: hazard ratio [HR], 1.8; P < .001); a diagnosis of metastatic esophagus, liver, lung, or pancreatic cancer, or melanoma ( v breast cancer, eg, esophagus HR, 1.89; P < .001); a greater number of comorbidities (American Hospital Formulary Service classes > 10 v 0: HR, 1.71; P < .001); and living in the Northeast (HR, 1.43; P < .001) or Midwest ( v South: HR, 1.39; P < .001) were the strongest predictors of shorter time from diagnosis to palliative care.CONCLUSION: Use of palliative care among commercially insured patients with advanced cancers has increased since 2001. However, even with an expanded definition of services specified as, or indicative of, palliative care, < 40% of patients with advanced cancers received palliative care in 2016.


  • Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States

    by Alessandra Ferrario, Xin Xu, Fang Zhang, Dennis Ross-Degnan, J. Frank Wharam, Anita K. Wagner

    PURPOSE: There is limited evidence on the intensity of end-of-life (EOL) care for women < 65 years old, who account for about 40% of breast cancer deaths in the United States. Using established indicators, we estimated the intensity of EOL care among these women.METHODS: We used 2000-2014 claims data from a large US insurer to identify women with metastatic breast cancer who, in the last month of their lives, had more than one hospital admission, emergency department visit, or an intensive care unit (ICU) admission and/or used antineoplastic therapy in the last 14 days of life. Using multivariate logistic regression, we assessed whether intensity of EOL care differed by demographic characteristics, socioeconomic factors, or regions.RESULTS: Adjusted estimates show an increase in EOL ICU admissions between 2000-2003 and 2010-2014 from 14% (95% CI, 10% to 17%) to 23% (95% CI, 20% to 26%) and a small increase in emergency department visits from 10% (95% CI, 7% to 13%) to 12% (95% CI, 9% to 15%), both statistically significant. There was no statistically significant change in the proportions of women experiencing more than one EOL hospitalization (14% in 2010-2014; 95% CI, 11% to 17%) and of those receiving EOL antineoplastic treatment (24% in 2010-2014; 95% CI, 21% to 27%). Living in predominantly mixed, Hispanic, Black, or Asian neighborhoods correlated with more intense care (odds ratio, 1.39; 95% CI, 1.10 to 1.77 for ICU).CONCLUSION: Consistent with findings in the Medicare population, our results suggest an overall increase in the number of ICU admissions at the EOL over time. They also suggest that patients from non-White neighborhoods receive more intense acute care.


  • Open Access

    What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool

    by Rosarin Sruamsiri, Alessandra Ferrario, Dennis Ross-Degnan, Avram E Denburg, A Lindsay Frazier, Sumit Gupta, Zachary J Ward, Jennifer M Yeh, Anita Katharina Wagner

    Objective Insufficient access to anticancer medicines may contribute to the wide survival differences of children with cancers across the globe. We developed a tool to estimate the volume of medicines and budget requirements to provide chemotherapy to children with acute lymphoblastic leukaemia (ALL). Design Development and application of an estimation tool. Setting Paediatric oncology hospital departments in Thailand. Participants 318 children aged 0–14 years diagnosed with ALL and 215 children with undiagnosed ALL. Interventions Estimates of volume and budget requirements for administering a full course of chemotherapy for ALL and a further course for children who relapse, according to National Treatment Guidelines. Primary and secondary outcome measures Primary outcome measures were the volume (mg) and cost (US$) of medicines needed to treat children with ALL. For medicines whose main indication is paediatric ALL (asparaginase and 6-mercaptopurine), we estimated the difference between volume needed and actual sales in 2017 (secondary outcome). Results Ten anticancer medicines and four chemoprotective agents are needed for the treatment of paediatric ALL according to the Thai treatment guidelines. Of these 14 medicines, 13 are included in the WHO essential medicines list for children. All are available as generics. We estimated that essential chemotherapy and chemoprotective agents to treat all children diagnosed with ALL in Thailand in 2017 would cost US$ 814 952 (US$ 1 365 422 for diagnosed and undiagnosed children), which corresponds to 0.005% (0.008%) of the country’s total health expenditure. The volumes of asparaginase and 6-mercaptopurine available on the Thai market in 2017 were more than sufficient (2.3 and 1.5 times the amounts needed, respectively) to treat all children diagnosed with ALL. Conclusions Procuring sufficient quantities of essential medicines to treat children with ALL requires relatively modest resources. Medicine cost should not be a major barrier to ALL treatment in similar settings.


  • Open Access

    Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand

    by Alessandra Ferrario, Peter Stephens, Xiaodong Guan, Dennis Ross-Degnan, Anita Wagner

    To assess sales of anti-cancer medicines in the 2017 World Health Organization’s WHO Model list of essential medicines in China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand from 2007 (2008 for Kazakhstan and Malaysia) to 2017. We extracted sales volume data for 39 anti-cancer medicines from the IQVIA database. We divided the total quantity sold by the reference defined daily dose to estimate the total number of defined daily doses sold, per country per year, for three types of anti-cancer therapies (traditional chemotherapy, targeted therapy and endocrine therapy). We adjusted these data by the number of new cancer cases in each country for each year. We observed an increase in sales across all types of anti-cancer therapies in all countries. The largest number of defined daily doses of traditional chemotherapy per new cancer case was sold in Thailand; however, the largest relative increase per new cancer case occurred in Indonesia (9.48-fold). The largest absolute and relative increases in sales of defined daily doses of targeted therapies per new cancer case occurred in Kazakhstan. Malaysia sold the largest number of adjusted defined daily doses of endocrine therapies in 2017, while China and Indonesia more than doubled their adjusted sales volumes between 2007 and 2017. The use of sales data can fill an important knowledge gap in the use of anti-cancer medicines, particularly during periods of insurance coverage expansion. Combined with other data, sales volume data can help to monitor efforts to improve equitable access to essential medicines.


  • Open Access

    Strategies to achieve fairer prices for generic and biosimilar medicines

    by Alessandra Ferrario, Guillaume Dedet, Tifenn Humbert, Sabine Vogler, Fatima Suleman, Hanne Bak Pedersen

    Early market entry and rapid uptake of quality assured generic and biosimilars are key to improving access to medicines, say Alessandra Ferrario and colleagues


  • Open Access

    The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists

    by Alessandra Ferrario, Ebiowei Samuel F Orubu, Moji Christianah Adeyeye, Muhammad H Zaman, Veronika J Wirtz


  • Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA

    by Patricia Vella Bonanno, Anna Bucsics, Steven Simoens, Antony P Martin, Wija Oortwijn, Jolanta Gulbinovič, Celia Rothe, Angela Timoney, Alessandra Ferrario, Mohamed Gad, et al.

    Introduction: In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): ‘Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU’. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve efficiency; there were however a number of concerns including its legal basis, the establishment of a single managing authority, the preservation of national jurisdiction over HTA decision making and the voluntary/mandatory uptake of joint assessments by Member States. Areas covered: This paper presents the consolidated views and considerations on the original Proposal as set by the European Commission of a number of policy makers, payers, experts from pricing and reimbursement authorities and academics from across Europe. Expert commentary: The Proposal has since been extensively discussed at Council and while good progress has been achieved, there are still divergent positions. The European Parliament gave a number of recommendations for amendments. If the Proposal is approved, it is important that balanced, improved outcome is achieved for all stakeholders. If not approved, the extensive contribution and progress attained should be sustained and preserved, and the best alternative solutions found.